- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05935527
Assess the Safety, Tolerability and Efficacy of Latanoprost Liposome for Lower Eyelid Steatoblepharon
January 18, 2024 updated by: Peregrine Ophthalmic
This trial is testing a drug to see if multiple injections to the undereye bags of selected patients decreases the volume of the eyebags as compared to placebo.
Subjects will be randomized to receive either one of two doses of POLAT-001 or placebo.
POLAT-001 will be injected into the eyebags at three of the visits.
Each subject will attend 7-10 clinic visits over 98 to 140 days total to assess efficacy and safety.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
This trial is a proof-of-concept trial and is testing a drug to see if multiple injections to the undereye bags of selected patients decreases the volume of the eyebags as compared to placebo.
Subjects will be randomized to receive either one of two doses of POLAT-001 (1 mg/mL or 2 mg/mL) or placebo (normal saline).
POLAT-001 will be injected into the eyebags at three of the visits.
Each subject will attend 7-10 clinic visits total over 98 to 140 days to assess efficacy and safety.
Subjects assigned to placebo will crossover to receive active treatment.
Efficacy will be determined using questionnaires and photography.
Safety will be assessed by subject-reported events and investigator observations of the subjects.
Study Type
Interventional
Enrollment (Estimated)
40
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Solomon Su, PhD
- Phone Number: 978-2046003
- Email: ssu@peregrinop.com
Study Contact Backup
- Name: Deborah Jezior
- Email: deb@dajezior.com
Study Locations
-
-
California
-
Newport Beach, California, United States, 92663
- Active, not recruiting
- Medical Associates, Inc.
-
-
Florida
-
Coral Gables, Florida, United States, 33146
- Recruiting
- Skin Associates of South Florida
-
Contact:
- Alex Cazzaniga
- Phone Number: 305-443-6606
-
-
Texas
-
Pflugerville, Texas, United States, 78660
- Active, not recruiting
- Austin Institute for Clinical Research
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Adult subjects, 22 years or older with moderate to severe convexity or fullness associated with periorbital fat.
- Subject has moderate to severe eyebags per Goldberg and Simon's Orbital Fat Grading System, per protocol requirements.
- Willing and able to attend all study visits.
Exclusion Criteria:
- Any signs or symptoms of periorbital disease in the study eye and related complications, as determined by the investigator.
- Active thyroid eye disease, chronic ocular inflammatory orbital disease or other ophthalmic disease that could confound study results.
- Evidence of infection, or clinically significant periocular, periorbital or conjunctival inflammation or conditions that in the opinion of the investigator would constitute a risk or could confound the study results.
- History of hypersensitivity to prostaglandin analogs or prostaglandin PF2alpha treatments.
- Known hypersensitivity to any component of the investigational product formulation.
- Use of periocular corticosteroids within 2 months prior to Screening.
- Use of intravitreal (IVT) injections within 3 weeks prior to Screening in the study eye.
- Surgical or laser treatment of the eye or surrounding anatomical structures within 6 months prior to Screening in the study eye.
- Previous history of lower incisional eyelid surgery.
- Previous history of undereye lid tattoo or underage lash extensions.
- Previous history of infra-orbital or anterior medical cheek fillers within 24 months prior to Screening.
- The subject has received botulinum toxin treatment of the inferior pretarsal orbicularis oculi muscle within 6 months of the first injection.
- History of ocular trauma in the study eye within 6 months prior to Screening.
- Any concurrent disease that would require medical or surgical intervention during the study in the study eye (e.g., retinal detachment, significant cataract, uncontrolled glaucoma).
- Facial nerve injury or abnormal weakness, other facial rejuvenation injections (not including botulinum toxin) in the treated area, facial surgery, or facial trauma within 3 months prior to Screening. History or concurrent systemic condition that would preclude the safe administration of the study treatment or confound the results of the safety (e.g., renal or hepatic impairment).
- Any laboratory findings that based on clinical assessment of the investigator would place the subject at risk or could confound th study results.
- Significant infraorbital vascular prominence.
- Women of childbearing potential who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control.
- Participation in an interventional clinical study within 30 days prior to Screening.
- Any other criterion that based on the clinical judgement of the investigator may place the subject at risk or confound study results.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo (Normal Saline)
Subjects will be randomized 1:5 (1 Placebo subject to 5 receiving active treatment) to receive placebo (Normal Saline) with a volume of 120 microliters injection.
|
Subjects will be randomized to receive three injections of 120 microliters total of Normal Saline per under eyebag at each of three treatment visits.
Other Names:
|
Experimental: POLAT-001
Subjects will be randomized 1:5 (1 Placebo subject to 5 receiving active treatment) to receive POLAT-001 with a volume of 120 microliters injection, at either 1 mg/mL or 2 mg/mL
|
Subjects will be randomized to receive three injections per under eyebag, either 1 mg/mL or 2 mg/mL and 120 microliter volume, at each of three treatment visits.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Mean change of photonumeric volume of eyebags in the POLAT-001 treated and placebo dose groups as measured by a 3D photography system
Time Frame: Baseline to 28 days after the last treatment cycle
|
Baseline to 28 days after the last treatment cycle
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Proportion of eyebags in the POLAT-001 treated and placebo dose groups with at least 10% reduction in photonumeric volume as measured by a 3D photography system
Time Frame: Baseline to 28 days after the last treatment
|
Baseline to 28 days after the last treatment
|
Proportion of eyebags in the POLAT-001 treated and placebo dose groups with at least 30% reduction in photonumeric volume as measured by a 3D photography system
Time Frame: Baseline to 28 days after the last treatment cycle
|
Baseline to 28 days after the last treatment cycle
|
Mean change in photonumeric volume of eyebags between the POLAT-001 treated high and low dose groups as measured by a 3D photography system
Time Frame: Baseline to 28 days after the last treatment cycle
|
Baseline to 28 days after the last treatment cycle
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 28, 2023
Primary Completion (Estimated)
May 1, 2024
Study Completion (Estimated)
June 1, 2024
Study Registration Dates
First Submitted
June 29, 2023
First Submitted That Met QC Criteria
June 29, 2023
First Posted (Actual)
July 7, 2023
Study Record Updates
Last Update Posted (Estimated)
January 19, 2024
Last Update Submitted That Met QC Criteria
January 18, 2024
Last Verified
June 1, 2023
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- POLAT-001-CS-402b
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lower Eyelid Steatoblepharon
-
Topokine Therapeutics, Inc.CompletedLower Eyelid Steatoblepharon (Excess Eyelid Fat)United States
-
SGM Physician Research ConsortiumMusculoskeletal Transplant FoundationCompletedLower Eyelid RetractionUnited States
-
University of California, IrvineBeckman Laser Institute University of California IrvineCompleted
-
Topokine Therapeutics, Inc.Completed
-
Topokine Therapeutics, Inc.Completed
-
The Royal Bournemouth HospitalCompletedLower Eyelid EntropionUnited Kingdom
-
University of EdinburghRoyal Free Hospital NHS Foundation Trust; National Health Service, United KingdomActive, not recruiting
-
University of MiamiCompleted
-
Montefiore Medical CenterRecruiting
-
University of California, San FranciscoCompletedAnesthesia, Local | Eyelid Tumor | Ophthalmology | Eyelid Bump | Eyelid Deformity | Eyelid Abscess | Eyelid Boil | Eyelid PapillomaUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States